Edward West v. Ortho-Mcneil Pharmaceutical Corporation

405 F.3d 578, 2005 U.S. App. LEXIS 6829, 86 Empl. Prac. Dec. (CCH) 41,954, 95 Fair Empl. Prac. Cas. (BNA) 961, 2005 WL 949050
CourtCourt of Appeals for the Seventh Circuit
DecidedApril 21, 2005
Docket03-3547, 03-3695
StatusPublished
Cited by16 cases

This text of 405 F.3d 578 (Edward West v. Ortho-Mcneil Pharmaceutical Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Edward West v. Ortho-Mcneil Pharmaceutical Corporation, 405 F.3d 578, 2005 U.S. App. LEXIS 6829, 86 Empl. Prac. Dec. (CCH) 41,954, 95 Fair Empl. Prac. Cas. (BNA) 961, 2005 WL 949050 (7th Cir. 2005).

Opinion

TERENCE T. EVANS, Circuit Judge.

In 1997, just a month before his 60th birthday, Edward West, an African-American male, was hired by a company called Innovex. Innovex provided pharmaceutical companies, like the defendant Ortho-McNeil Pharmaceutical Corporation (OMPC), with contract sales representatives. Two years later, in 1999, OMPC hired West (and 10 other Innovex employees) as a direct sales representative of the *579 company. OMPC terminated West in July of 2000 for, it claimed, violations of company policies. West thought the termination was caused by his race and age.

After West filed suit, the district court granted, in part, OMPC’s motion for summary judgment, leaving only two issues for trial: whether OMPC was motivated by race in terminating West, and whether his supervisor, Walter Pascale, approved of West’s distribution of certain “homemade” promotional sales materials. Prior to starting the trial, the court ruled in limine that seven of eight racially offensive statements Pascale was alleged to have made were excluded as being too remote in time from the termination.

Trial commenced with West representing himself. At the close of his case-in-chief, the district court granted OMPC’s motion, pursuant to Federal Rule of Civil Procedure 50, for judgment as a matter of law. West appeals from that decision, from the exclusion of seven of Pascale’s statements, and, apparently, from an award of costs to OMPC. We say “apparently” because nothing in the briefing or at argument makes reference to this issue.

The facts show that, as an OMPC sales representative, West was responsible for promoting several OMPC drugs to customers within his assigned sales territory, including Holy Cross Hospital. One of the drugs was Levaquin. West worked with another sales representative in his territory, Cheryl Janicek.

West’s supervisor for almost the entire time he worked for OMPC was Pascale. Pascale, if West is believed, had a rather nasty habit of making racially offensive statements. The seven which were excluded from the trial are, first, in 1997 that a “Caucasian could do a better job.” In August 1998, he said his family lived on the south side of Chicago but that “blacks had run them out of the area.” In September, he said “Blacks were stupid” and that “President Clinton wasn’t doing anything but selling blacks out.” In October 1998, he gave West’s territory in the western Chicago suburbs to a white woman because “he believed that a white female would have a greater success.” In the summer of 1999, Pascale told West to concentrate his efforts in Oak Park and Evergreen Park because he “did not like having to observe West in areas where Blacks and Hispanics were.” That summer, he also said that “Hispanics and Blacks have nothing but babies and always end up on welfare.” In the fall of that year, an African-American man arrived late for a picnic, and Pascale’s comment was “just like a nigger, they’re always late.” These statements, as we said, were excluded by, the court. The final statement, which was admitted, was that in March 2000, Pascale called West an “asinine nigger” or an “asinine black.” West testified to the former on direct examination and the latter on cross.

But despite this evidence (again, if true) of Pascale’s bias, OMPC says there is no discrimination. OMPC says that Pascale was not the decisionmaker on West’s termination, and that the termination was based on a company rules violation. In July 2000, West was concerned about the possibility that Holy Cross Hospital might replace OMPC’s product Levaquin on for-mulary at the hospital with a product of a competing drug company, a product called Tequin. To convince Holy Cross to stay with Levaquin, West compiled a packet of materials (referred to as homemade materials because they were not prepared by the company itself). He says he obtained Pascale’s approval of the materials and that the common practice at OMPC was that Pascale’s approval was final. The materials included a Levaquin package insert, an article from “The Medical Letter,” *580 a copy of the product insert for Tequin, a copy of a fax from the Federal Drug Administration to the manufacturer of Te-quin, with a notation West made on the top that “FYI, FDA FINED COMPANY $17 MILLION FOR MISREPRESENTING PRODUCT,” two articles from the Wall Street Journal discussing punitive damage awards, an article from a journal known as Formulary, and an article from the periodical AmeriNet. The real problem with the materials from OMPC’s point of view, however, was the cover letter. And, importantly, Pascale denied seeing the letter before it was sent out; West, on the other hand, says he read it to Pascale over the telephone. West sent the materials to the then-interim president of Holy Cross and to 39 additional physicians and administrators associated with the hospital.

The cover letter said, in part:

I implore you not to let Holy Cross Hospital become the victim of some huge punitive-damage award or ruin the hospital’s image.... This could occur at Holy Cross because of an impending decision to replace the proven and safe Levaquin antibiotic with a new antibiotic that has no history and a dubious efficacy and safety profile, but is $2 dollars cheaper.
The antibiotic under consideration to replace Levaquin ... [h]as a bolded package insert warning regarding QTc prolongation (this could cause instantaneous death).

Janicek told Pascale that West sent the letter, and Pascale immediately contacted his supervisor, the regional business director Cathie Taylor, who asked him to fax it to her. Pascale and Taylor both contend that Pascale offered no opinion about whether the letter violated OMPC policy and made no recommendation regarding what action OMPC should take.

Taylor concluded that the cover letter violated several OMPC policies. She determined that it was an “unapproved promotional piece” and therefore violated the rule against such materials, which include homemade sales materials:

The company has always had a strong policy against the creation and use of unofficial sales materials. There are no exceptions. SALES REPRESENTATIVES FOUND TO HAVE ISSUED THEIR OWN SALES MATERIALS OF ANY KIND WILL BE SUBJECT TO TERMINATION.

Another rule violated, in Taylor’s opinion, was the rule against the disparagement of competitors.

Taylor believed that the letter was a violation requiring discipline. She informed her superior and recommended that West’s employment be terminated. Her recommendation was followed.

West contends that his testimony at trial raised an issue of fact for the jury that, in accordance with OMPC policy, Pascale approved his use of the homemade materials. West testified that he was treated differently than Pascale and Janicek, who were not terminated for violating the rule against homemade promotional materials. He testified that Pascale instructed West and other salespersons to violate company rules on several occasions. In short, West thinks Pascale encouraged him to prepare the materials and then used them against him, all out of racial bias.

Under that theory, West also contends Pascale was behind his termination.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Staub v. Hy-Vee, Inc.
C.D. Illinois, 2022
Vassileva v. City of Chicago
N.D. Illinois, 2018
Macias v. Bakersfield Restaurant, LLC
54 F. Supp. 3d 922 (N.D. Illinois, 2014)
KUNTZMAN v. Wal-Mart
673 F. Supp. 2d 690 (N.D. Indiana, 2009)
Fischer, Barbara v. Avanade
Seventh Circuit, 2008
Fischer v. Avanade, Inc.
519 F.3d 393 (Seventh Circuit, 2008)
Justise, Charles E. v. Zenith Logistics
186 F. App'x 680 (Seventh Circuit, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
405 F.3d 578, 2005 U.S. App. LEXIS 6829, 86 Empl. Prac. Dec. (CCH) 41,954, 95 Fair Empl. Prac. Cas. (BNA) 961, 2005 WL 949050, Counsel Stack Legal Research, https://law.counselstack.com/opinion/edward-west-v-ortho-mcneil-pharmaceutical-corporation-ca7-2005.